A Phase 3 interventional study of Ibuprofen 300 mg Oral Tablet and Ibuprofen 200 mg Oral Tablet in Pain, sponsored by Reckitt Benckiser Healthcare (UK) Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-06-03.
Sponsored by Reckitt Benckiser Healthcare (UK) Limited (part of Reckitt) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.
Among the 86 studies testing ibuprofen in Pain, this one is the 16th largest by enrollment, is one of 4 that started in 2019, is one of 22 in phase 3, and was the 62nd registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:
Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi · Sites in Pakistan
Ages 18–60
October University for Modern Sciences and Arts · Sites in Egypt
Ages 6–12
Armed Forces Institute of Dentistry, Pakistan · Sites in Pakistan
Ages 18–50 · Healthy volunteers
Ankara City Hospital Bilkent · Sites in Turkey
Ages 18–80
Benaroya Research Institute · Sites in United States
Ages 18+ · Men only · Healthy volunteers
By country, each count listing its studies:
Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 10 · Phase 3 22 · Phase 4 30
First in 1998; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 280 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 100 across the 86 interventional studies. Of the 69 that completed or were terminated, 32 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 86 have an industry lead sponsor. The 10 most frequent:
This study is registered under Reckitt Benckiser Healthcare (UK) Limited, one of the names counted as Reckitt. Under that name alone:
Reckitt Benckiser Healthcare (UK) Limited is the lead sponsor of 35 studies on the registry; none are open to participants now.
Reckitt has 1 study filed under Pain — fewer than ten, so there is no comparison to draw.
2 of the studies testing ibuprofen in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07512297University of GaziantepPain Control During ESWL Using Non-Opioid Analgesics | 2027-01-01 |
| NCT07275710Armed Forces Post Graduate Medical Institute (AFPGMI), RawalpindiRole of Alprazolam in Management of Post Endodontic Pain After Single Visit Root Canal Treatment. To Compare Mean Pain Score Between Two Group of Participants Undergoing Post Operative Pain Management After Single Visit Root Canal Treatment: NSAIDs Alone and a Combination of NSAIDs and Alprazolam. | 2027-01-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 86 studies testing ibuprofen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a single centre, randomised, double-blind, double-dummy, parallel group, multiple-dose, active and placebo-controlled efficacy study to evaluate the efficacy and safety of 2×300mg ibuprofen Prolonged Release (PR) tablets in subjects with postoperative dental pain.
This is a single centre, randomised, double-blind, double-dummy, parallel group, multiple-dose, active and placebo controlled efficacy study to evaluate the efficacy and safety of ibuprofen 2 × 300 mg ibuprofen PR tablets in subjects with postoperative dental pain.
Eligible subjects will complete all screening procedures within 28 days before the surgery and randomisation.
At Screening, subjects will provide written informed consent to participate in the study before any protocol specified procedures or assessments are completed. On Day 1, subjects who continue to be eligible for study participation after completing screening procedures and assessments will undergo extraction of 2 or more third molars. At least 1 of the third molars must be a fully or partially bone impacted mandibular molar. If only 2 molars are removed, then they must be ipsilateral.
All subjects will receive local anaesthesia (2% lidocaine with 1:100,000 epinephrine). Nitrous oxide will be allowed at the discretion of the investigator. Subjects who experience moderate to severe pain intensity (a score of ≥5 on a numeric rating scale [NRS] from 0-10 where 0 = no pain, 10 = worst pain ever) within 6 hours after surgery and who continue to meet all study entry criteria will be randomised in a 3:3:1 ratio to receive 2 × 300 mg ibuprofen PR tablets every 12 hours (Q12h), 2 × 200 mg ibuprofen immediate release (IR) tablets every 8 hours (Q8h), or placebo. The randomisation will be stratified by baseline pain category (moderate or severe) using a categorical scale that includes the categories of none (0), mild (1-4), moderate (5-7), and severe (8-10).
Subjects will re-assess their baseline pain intensity using the NRS immediately before receiving study drug (pre-dose, Time 0) and their pain intensity (NRS) and pain relief (5-point categorical scale) at the following time points (pre-dose, if at one of the dosing time points of 0, 8, 12 and/or 16 hours): 15, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, and 24 hours after Time 0; and immediately before each dose of rescue medication, if any. For assessments less than 1 hour apart a window of +/-2 min is allowable whilst for assessments at least 1 hour apart a +/-5 min window is allowable.
The double stopwatch method will be used to record the time to perceptible pain relief and time to meaningful pain relief during the 8 hours following the first dose or until subject takes rescue medication. Subjects will complete a global evaluation of study drug 24 hours (+/- 5 minutes) after Time 0 or immediately before the first dose of rescue medication (whichever occurs first). Vital signs will be recorded after the subject has been in a sitting position for 3 minutes at the following times: before surgery, within 30 minutes before Time 0, 12 and 24 hours after Time 0, and/or immediately before the first dose of rescue medication. Adverse events (AEs) will be monitored and recorded from the time of signing of the informed consent form (ICF) until the Follow-up Visit (or Early Termination Visit). During the 24 hours following Time 0, subjects will complete efficacy and safety assessments. Subjects will remain at the study site overnight and will be discharged on Day 2.
Paracetamol / acetaminophen (1000 mg) will be permitted as the initial rescue medication. Subjects will be encouraged to wait at least 60 minutes after receiving study drug before taking rescue medication. If acetaminophen rescue medication is not effective in relieving the subject's pain, 5 mg oxycodone rescue medication may be administered at the discretion of the investigator.
Subjects are not permitted to take any concomitant medications that might confound assessments of pain relief, such as psychotropic drugs, antidepressants, sedative-hypnotics (other than those permitted for conscious sedation), or other analgesics taken within five times of their elimination half-lives (other than those used at the surgery). Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) are permitted if the subject has been on a stable dose for at least four weeks prior to Visit 1 (screening).
Other restrictions include the following: alcohol use is prohibited from 24 hours before surgery until discharge on Day 2; nothing by mouth from midnight before surgery until 1 hour after surgery; clear liquids only are allowed starting 1 hour after surgery until 1 hour after dosing; 1 hour after dosing, the subject's diet may be advanced according to standard practice.
Upon discharge from the study site, subjects may be prescribed pain medication for use at home according to the standard practice of the study site. On Day 8 (± 2 days), subjects will return to the study site for an abbreviated confirmatory physical assessment and AE assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be considered not of child-bearing potential, females must be surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or (defined as no menses for 12 months without an alternative medical cause).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 × 300 mg ibuprofen PR tablets at Hours 0 and 12 2 × placebo of PR tablets at Hours 8 and 16 2 × placebo of IR tablets at Hours 0, 8, 12, and 16
Drug: Ibuprofen 300 mg Oral Tablet · Drug: Placebo of PR tablet · Drug: Placebo of IR tablet
2 × 200 mg ibuprofen IR tablets at Hours 0, 8, and 16 2 × placebo of IR tablets at Hour 12 2 × placebo of PR tablets at Hours 0, 8, 12, and 16
Drug: Ibuprofen 200 mg Oral Tablet · Drug: Placebo of PR tablet · Drug: Placebo of IR tablet
2 × placebo of PR tablets at Hours 0, 8, 12, and 16 2 × placebo of IR tablets at Hours 0, 8, 12, and 16
Drug: Placebo of PR tablet · Drug: Placebo of IR tablet
2 × 300 mg tablets at Hours 0 and 12
Also known as: Prolonged Release Tablet
2 × 200 mg tablets at Hours 0, 8, and 16
Also known as: Nurofen, Immediate Release Tablet
2 tablets up to four times in 24 hours
2 tablets up to four times in 24 hours
Summed Pain Intensity Difference Over 0 to 12 Hours (SPID12) After Time 0
SPID12 was used to compare the test product (2 × 300 mg ibuprofen PR tablets) and comparator product (2 × 200 mg ibuprofen IR tablets three times a day \[TID\]) against the placebo product. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain. SPID12 was calculated using the summed pain intensity difference (change from Time 0) under the NRS-time curve from 15 minutes through 12 hours calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of SPID12 is 0 (no change in pain intensity from Time 0 to 12 hours); the theoretical maximum is 120 (if a patient had a score of 10 \[worst pain intensity\] at baseline, which decreased to 0 \[no pain\] at the next time point and remained at 0 after); a higher SPID12 score indicates a better outcome.
Time frame: 0-12 hours
Summed Pain Intensity Difference Over 0 to 24 Hours (SPID24) After Time 0
SPID24 was used to compare the test product (2 × 300 mg ibuprofen PR tablets BID) and comparator product (2 × 200 mg ibuprofen IR tablets TID) against the placebo product. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain. SPID24 was calculated using the summed pain intensity difference (change from Time 0) under the NRS-time curve from 15 minutes through 24 hours calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of SPID24 is 0 (no change in pain intensity from Time 0 to 24 hours); the theoretical maximum is 240 (if a patient had a score of 10 \[worst pain intensity\] at baseline, which decreased to 0 \[no pain\] at the next time point and remained at 0 after).
Time frame: 0-24 hours
Summed Pain Intensity Difference Over 0 to 4 Hours (SPID4) After Time 0
SPID4 was used to compare the test product (2 × 300 mg ibuprofen PR tablets BID) and comparator product (2 × 200 mg ibuprofen IR tablets TID) against the placebo product. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain. SPID4 was calculated using the summed pain intensity difference (change from Time 0) under the NRS-time curve from 15 minutes through 4 hours calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of SPID4 is 0 (no change in pain intensity from Time 0 to 4 hours); the theoretical maximum is 40 (if a patient had a score of 10 \[worst pain intensity\] at baseline, which decreased to 0 \[no pain\] at the next time point and remained at 0 after).
Time frame: 0-4 hours
Summed Pain Intensity Difference Over 0 to 8 Hours (SPID8) After Time 0
SPID8 was used to compare the test product (2 × 300 mg ibuprofen PR tablets BID) and comparator product (2 × 200 mg ibuprofen IR tablets TID) against the placebo product. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain. SPID8 was calculated using the summed pain intensity difference (change from Time 0) under the NRS-time curve from 15 minutes through 8 hours calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of SPID8 is 0 (no change in pain intensity from Time 0 to 8 hours); the theoretical maximum is 80 (if a patient had a score of 10 \[worst pain intensity\] at baseline, which decreased to 0 \[no pain\] at the next time point and remained at 0 after).
Time frame: 0-8 hours
Sum of Total Pain Relief Over 0 to 4 Hours (TOTPAR4) After Time 0
A 5-point categorical Pain Relief Scale (PRS) with choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4 was completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome. TOTPAR4 is the total pain relief measured by the PRS from 15 minutes through 4 hours, calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of TOTPAR4 is 0 (no pain relief from Time 0 to 4 hours); the theoretical maximum is 16 (if a patient experiences maximum pain relief at all time points after baseline).
Time frame: 0-4 hours
Sum of Total Pain Relief Over 0 to 8 Hours (TOTPAR8) After Time 0
A 5-point categorical Pain Relief Scale (PRS) with choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4 was completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome. TOTPAR8 is the total pain relief measured by the PRS from 15 minutes through 8 hours, calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of TOTPAR8 is 0 (no pain relief from Time 0 to 8 hours); the theoretical maximum is 32 (if a patient experiences maximum pain relief at all time points after baseline).
Time frame: 0-8 hours
Sum of Total Pain Relief Over 0 to 12 Hours (TOTPAR12) After Time 0
A 5-point categorical Pain Relief Scale (PRS) with choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4 was completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome. TOTPAR12 is the total pain relief measured by the PRS from 15 minutes through 12 hours, calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of TOTPAR12 is 0 (no pain relief from Time 0 to 12 hours); the theoretical maximum is 48 (if a patient experiences maximum pain relief at all time points after baseline).
Time frame: 0-12 hours
Sum of Total Pain Relief Over 0 to 24 Hours (TOTPAR24) After Time 0
A 5-point categorical Pain Relief Scale (PRS) with choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4 was completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome. TOTPAR24 is the total pain relief measured by the PRS from 15 minutes through 24 hours, calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of TOTPAR24 is 0 (no pain relief from Time 0 to 24 hours); the theoretical maximum is 96 (if a patient experiences maximum pain relief at all time points after baseline).
Time frame: 0-24 hours
Summed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 4 Hours (SPRID4) After Time 0
The summed pain relief and intensity difference (sum of TOTPAR and SPID \[SPRID\]) over 0 to 4 hours (SPRID4) was determined by calculating the difference in the PRS at the 4-hour time point and the 0-hour time point (TOTPAR4) and adding this value to the difference in the NRS for pain at the 4-hour time point and the 0-hour time point (SPID4). The minimum value of SPRID4 is 0; the theoretical maximum is 56; a higher SPRID4 score indicates a better outcome.
Time frame: 0-4 hours
Summed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 8 Hours (SPRID8) After Time 0
The summed pain relief and intensity difference (sum of TOTPAR and SPID \[SPRID\]) over 0 to 8 hours (SPRID8) was determined by calculating the difference in the PRS at the 8-hour time point and the 0-hour time point (TOTPAR8) and adding this value to the difference in the NRS for pain at the 8-hour time point and the 0-hour time point (SPID8). The minimum value of SPRID8 is 0; the theoretical maximum is 112; a higher SPRID8 score indicates a better outcome.
Time frame: 0-8 hours
Summed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 12 Hours (SPRID12) After Time 0
The summed pain relief and intensity difference (sum of TOTPAR and SPID \[SPRID\]) over 0 to 12 hours (SPRID12) was determined by calculating the difference in the PRS at the 12-hour time point and the 0-hour time point (TOTPAR12) and adding this value to the difference in the NRS for pain at the 12-hour time point and the 0-hour time point (SPID12). The minimum value of SPRID12 is 0; the theoretical maximum 168; a higher SPRID12 score indicates a better outcome.
Time frame: 0-12 hours
Summed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 24 Hours (SPRID24) After Time 0
The summed pain relief and intensity difference (sum of TOTPAR and SPID \[SPRID\]) over 0 to 24 hours (SPRID24) was determined by calculating the difference in the PRS at the 24-hour time point and the 0-hour time point (TOTPAR24) and adding this value to the difference in the NRS for pain at the 24-hour time point and the 0-hour time point (SPID24). The minimum value of SPRID24 is 0; the theoretical maximum is 336; a higher SPRID24 score indicates a better outcome.
Time frame: 0-24 hours
Number of Subjects With Response to Study Drug
A responder was defined as a subject with ≥30% improvement in pain intensity at the 8-hour assessment without rescue medication during the first 8 hours. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain.
Time frame: 0-8 hours
Numeric Rating Scale (NRS) Pain Intensity Difference (PID) at Each Time Point After Time 0
An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain, and the PID (the difference in NRS pain intensity between each time point and Time 0) at each time point was calculated.
Time frame: 0-24 hours
Pain Intensity Score at Each Scheduled Time Point After Time 0
Pain intensity score at each scheduled time point will be assessed using a numeric rating scale (NRS) for pain. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain.
Time frame: 0-24 hours
Pain Relief at Each Scheduled Time Point After Time 0
Pain relief score at each scheduled time point after Time 0 was measured using the Pain Relief Scale (PRS). The PRS was used to measure pain relief and is a 5-point categorical scale, with response choices of: none = 0; a little = 1; some = 2; a lot = 3; and complete = 4 to be completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome.
Time frame: 0-24 hours
Peak Pain Relief
Peak pain relief at each time point was measured using the Pain Relief Scale (PRS). The PRS was used to measure pain relief and is a 5-point categorical scale, response choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4 to be completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome. For each subject, peak pain relief was calculated as the maximum pain relief over all PRS assessments, and summarised by counts (and percentages) for each PRS score. Peak pain relief was calculated from PRS scores that were adjusted for rescue medication usage using windowed worst observation carried forward (WOCF).
Time frame: 0-24 hours
Time to Onset of Analgesia (Measured as Time to Perceptible Pain Relief Confirmed by Time to Meaningful Pain Relief) Using Double Stopwatch
Two stopwatches were started immediately after the subject swallowed the study drug. Subjects were instructed to, "Stop the first stopwatch when you first feel any pain relief whatsoever. This does not mean you feel completely better, although you might, but when you first feel any relief in the pain you have now" (perceptible pain relief), and then, "Stop the second stopwatch when you feel the pain relief is meaningful to you" (meaningful pain relief). If the stopwatches were not stopped within 8 hours after Time 0 use of the stopwatches was discontinued. If the subject had meaningful pain relief (i.e., pressed both stopwatches) then time to onset of analgesia was date/time of perceptible pain relief - date/time of the first dose of study drug. Values presented are from Kaplan-Meier estimates.
Time frame: 0-24 hours
Time to First Perceptible Pain Relief
Two stopwatches were started immediately after the subject swallowed the study drug. Subjects were instructed to, "Stop the first stopwatch when you first feel any pain relief whatsoever. This does not mean you feel completely better, although you might, but when you first feel any relief in the pain you have now" (perceptible pain relief). Time to first perceptible pain relief was date/time of the first reported pain relief (any) as assessed by the subject (i.e., when the subject stopped the first stopwatch, irrespective of the second) - date/time of the first dose of study drug. If the stopwatch were not stopped within 8 hours after Time 0, use of the stopwatches was discontinued. Values presented are from Kaplan-Meier estimates.
Time frame: 0-8 hours
Time to Meaningful Pain Relief
Two stopwatches were started immediately after the subject swallowed the study drug. Each subject was instructed, "Stop the second stopwatch when you feel the pain relief is meaningful to you" (meaningful pain relief). Time to meaningful pain relief was the date/time of the first reported meaningful (subjective) pain relief as assessed by the subject (i.e., when the subject stopped the second stopwatch) - date/time of the first dose of study drug. If the stopwatches were not stopped within 8 hours after Time 0 use of the stopwatches was discontinued. Values presented are from Kaplan-Meier estimates.
Time frame: 0-8 hours
Time to Peak Pain Relief
The PRS was used to measure pain relief and is a 5-point categorical scale, with response choices of: none = 0; a little = 1; some = 2; a lot = 3; and complete = 4 to be completed in response to the question "How much relief have you had since your starting pain?". A higher score indicates greater pain. Time to peak pain relief was the time when peak pain relief (PPR) first occurred. Values presented are from Kaplan-Meier estimates.
Time frame: 0-24 hours
Number of Subjects Using Rescue Medication
After randomisation and administration of study drug, paracetamol/acetaminophen (1000 mg) was permitted as the initial rescue medication. Subjects were encouraged to wait at least 60 minutes after receiving study drug before taking rescue medication. If acetaminophen rescue medication was not effective in relieving the subject's pain, 5 mg oxycodone rescue medication was administered at the discretion of the investigator. At the investigator's discretion, repeat doses of rescue medication were also administered as required.
Time frame: 0-24 hours
Time to First Use of Rescue Medication (Median and 95% Confidence Interval)
Time to first use of rescue medication, in hours.
Time frame: 0-24 hours
Time to First Use of Rescue Medication (Hazard Ratios Versus Placebo)
Time to first use of rescue medication, in hours. Values presented are the hazard ratios, calculated from Cox proportional hazards model with treatment group as a categorical factor and baseline pain as a continuous covariate. A hazard ratio of \<1 means that when subjects did take rescue medication, subjects in the ibuprofen groups refrained from taking rescue medication for longer than subjects in the placebo group. A hazard ratio of \>1 means that when subjects did take rescue medication, subjects in the placebo group refrained from taking rescue medication for longer than subjects in the ibuprofen groups.
Time frame: 0-24 hours
Incidence of Treatment Emergent Adverse Events as Assessed by Patient Response to Questions and Spontaneous Reporting of TEAEs
Incidence of treatment emergent adverse events (TEAEs). Data listings will be provided for protocol specified safety data.
Time frame: 0-10 days
Vital Signs Measurements - Blood Pressure in mm/Hg
Incidence of changes in vital sign measurements. Descriptive statistics will be provided at each scheduled time point for each treatment group. Changes from Baseline for vital signs will be calculated for each subject.
Time frame: 0-10 days
Vital Signs Measurements - Heart Rate in Beats Per Minute
Incidence of changes in vital sign measurements. Descriptive statistics will be provided at each scheduled time point for each treatment group. Changes from Baseline for vital signs will be calculated for each subject.
Time frame: 0-10 days
Vital Signs Measurements - Respiratory Rate in Breaths Per Minute
Incidence of changes in vital sign measurements. Descriptive statistics will be provided at each scheduled time point for each treatment group. Changes from Baseline for vital signs will be calculated for each subject.
Time frame: 0-10 days
Vital Signs Measurements - Body Temperature in ºC
Incidence of changes in vital sign measurements. Descriptive statistics will be provided at each scheduled time point for each treatment group. Changes from Baseline for vital signs will be calculated for each subject.
Time frame: 0-10 days
Global Evaluation of Efficacy Using 5 Point Categorical Scale
Patient's global evaluation of study drug using 5 point categorical scale, response choices of 0 = poor, 1 = fair, 2 = good, 3 = very good, or 4 = excellent to be completed by the patient in response to the question "How effective do you think the study drug is as a treatment for pain?". Subjects will complete the global evaluation of study drug 24 hours after Time 0 or immediately before the first dose of rescue medication (whichever occurs first).
Time frame: 0-24 hours
| Milestone | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Started | 120 | 120 | 40 |
| Completed | 111 | 112 | 35 |
| Not completed | 9 | 8 | 5 |
SPID12 was used to compare the test product (2 × 300 mg ibuprofen PR tablets) and comparator product (2 × 200 mg ibuprofen IR tablets three times a day \[TID\]) against the placebo product. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain. SPID12 was calculated using the summed pain intensity difference (change from Time 0) under the NRS-time curve from 15 minutes through 12 hours calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of SPID12 is 0 (no change in pain intensity from Time 0 to 12 hours); the theoretical maximum is 120 (if a patient had a score of 10 \[worst pain intensity\] at baseline, which decreased to 0 \[no pain\] at the next time point and remained at 0 after); a higher SPID12 score indicates a better outcome.
| score on a scale*hours | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Summed Pain Intensity Difference Over 0 to 12 Hours (SPID12) After Time 0 | 51.84 ± 21.457 | 56.33 ± 18.769 | 19.11 ± 24.630 |
SPID24 was used to compare the test product (2 × 300 mg ibuprofen PR tablets BID) and comparator product (2 × 200 mg ibuprofen IR tablets TID) against the placebo product. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain. SPID24 was calculated using the summed pain intensity difference (change from Time 0) under the NRS-time curve from 15 minutes through 24 hours calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of SPID24 is 0 (no change in pain intensity from Time 0 to 24 hours); the theoretical maximum is 240 (if a patient had a score of 10 \[worst pain intensity\] at baseline, which decreased to 0 \[no pain\] at the next time point and remained at 0 after).
| score on a scale*hours | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Summed Pain Intensity Difference Over 0 to 24 Hours (SPID24) After Time 0 | 115.75 ± 46.146 | 121.90 ± 37.263 | 64.32 ± 55.070 |
SPID4 was used to compare the test product (2 × 300 mg ibuprofen PR tablets BID) and comparator product (2 × 200 mg ibuprofen IR tablets TID) against the placebo product. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain. SPID4 was calculated using the summed pain intensity difference (change from Time 0) under the NRS-time curve from 15 minutes through 4 hours calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of SPID4 is 0 (no change in pain intensity from Time 0 to 4 hours); the theoretical maximum is 40 (if a patient had a score of 10 \[worst pain intensity\] at baseline, which decreased to 0 \[no pain\] at the next time point and remained at 0 after).
| score on a scale*hours | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Summed Pain Intensity Difference Over 0 to 4 Hours (SPID4) After Time 0 | 14.68 ± 9.752 | 16.99 ± 7.884 | 1.24 ± 8.346 |
SPID8 was used to compare the test product (2 × 300 mg ibuprofen PR tablets BID) and comparator product (2 × 200 mg ibuprofen IR tablets TID) against the placebo product. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain. SPID8 was calculated using the summed pain intensity difference (change from Time 0) under the NRS-time curve from 15 minutes through 8 hours calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of SPID8 is 0 (no change in pain intensity from Time 0 to 8 hours); the theoretical maximum is 80 (if a patient had a score of 10 \[worst pain intensity\] at baseline, which decreased to 0 \[no pain\] at the next time point and remained at 0 after).
| score on a scale*hours | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Summed Pain Intensity Difference Over 0 to 8 Hours (SPID8) After Time 0 | 33.13 ± 16.195 | 34.48 ± 13.001 | 11.00 ± 14.571 |
A 5-point categorical Pain Relief Scale (PRS) with choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4 was completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome. TOTPAR4 is the total pain relief measured by the PRS from 15 minutes through 4 hours, calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of TOTPAR4 is 0 (no pain relief from Time 0 to 4 hours); the theoretical maximum is 16 (if a patient experiences maximum pain relief at all time points after baseline).
| score on a scale*hours | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Sum of Total Pain Relief Over 0 to 4 Hours (TOTPAR4) After Time 0 | 8.08 ± 4.337 | 8.98 ± 3.365 | 1.98 ± 3.285 |
A 5-point categorical Pain Relief Scale (PRS) with choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4 was completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome. TOTPAR8 is the total pain relief measured by the PRS from 15 minutes through 8 hours, calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of TOTPAR8 is 0 (no pain relief from Time 0 to 8 hours); the theoretical maximum is 32 (if a patient experiences maximum pain relief at all time points after baseline).
| score on a scale*hours | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Sum of Total Pain Relief Over 0 to 8 Hours (TOTPAR8) After Time 0 | 18.08 ± 7.314 | 18.41 ± 5.764 | 7.89 ± 5.642 |
A 5-point categorical Pain Relief Scale (PRS) with choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4 was completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome. TOTPAR12 is the total pain relief measured by the PRS from 15 minutes through 12 hours, calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of TOTPAR12 is 0 (no pain relief from Time 0 to 12 hours); the theoretical maximum is 48 (if a patient experiences maximum pain relief at all time points after baseline).
| score on a scale*hours | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Sum of Total Pain Relief Over 0 to 12 Hours (TOTPAR12) After Time 0 | 28.13 ± 9.981 | 29.981 ± 8.538 | 12.76 ± 9.270 |
A 5-point categorical Pain Relief Scale (PRS) with choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4 was completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome. TOTPAR24 is the total pain relief measured by the PRS from 15 minutes through 24 hours, calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of TOTPAR24 is 0 (no pain relief from Time 0 to 24 hours); the theoretical maximum is 96 (if a patient experiences maximum pain relief at all time points after baseline).
| score on a scale*hours | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Sum of Total Pain Relief Over 0 to 24 Hours (TOTPAR24) After Time 0 | 62.32 ± 20.504 | 64.63 ± 16.774 | 36.96 ± 22.153 |
The summed pain relief and intensity difference (sum of TOTPAR and SPID \[SPRID\]) over 0 to 4 hours (SPRID4) was determined by calculating the difference in the PRS at the 4-hour time point and the 0-hour time point (TOTPAR4) and adding this value to the difference in the NRS for pain at the 4-hour time point and the 0-hour time point (SPID4). The minimum value of SPRID4 is 0; the theoretical maximum is 56; a higher SPRID4 score indicates a better outcome.
| score on a scale*hours | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Summed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 4 Hours (SPRID4) After Time 0 | 22.76 ± 13.870 | 25.97 ± 11.011 | 3.22 ± 11.464 |
The summed pain relief and intensity difference (sum of TOTPAR and SPID \[SPRID\]) over 0 to 8 hours (SPRID8) was determined by calculating the difference in the PRS at the 8-hour time point and the 0-hour time point (TOTPAR8) and adding this value to the difference in the NRS for pain at the 8-hour time point and the 0-hour time point (SPID8). The minimum value of SPRID8 is 0; the theoretical maximum is 112; a higher SPRID8 score indicates a better outcome.
| score on a scale*hours | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Summed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 8 Hours (SPRID8) After Time 0 | 51.21 ± 22.985 | 52.88 ± 18.156 | 18.89 ± 19.916 |
The summed pain relief and intensity difference (sum of TOTPAR and SPID \[SPRID\]) over 0 to 12 hours (SPRID12) was determined by calculating the difference in the PRS at the 12-hour time point and the 0-hour time point (TOTPAR12) and adding this value to the difference in the NRS for pain at the 12-hour time point and the 0-hour time point (SPID12). The minimum value of SPRID12 is 0; the theoretical maximum 168; a higher SPRID12 score indicates a better outcome.
| score on a scale*hours | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Summed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 12 Hours (SPRID12) After Time 0 | 79.97 ± 30.643 | 86.24 ± 26.260 | 31.87 ± 33.539 |
The summed pain relief and intensity difference (sum of TOTPAR and SPID \[SPRID\]) over 0 to 24 hours (SPRID24) was determined by calculating the difference in the PRS at the 24-hour time point and the 0-hour time point (TOTPAR24) and adding this value to the difference in the NRS for pain at the 24-hour time point and the 0-hour time point (SPID24). The minimum value of SPRID24 is 0; the theoretical maximum is 336; a higher SPRID24 score indicates a better outcome.
| score on a scale*hours | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Summed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 24 Hours (SPRID24) After Time 0 | 178.07 ± 64.783 | 186.53 ± 51.842 | 101.28 ± 76.562 |
A responder was defined as a subject with ≥30% improvement in pain intensity at the 8-hour assessment without rescue medication during the first 8 hours. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain.
| Participants | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Number of Subjects With Response to Study Drug | 81 | 76 | 5 |
An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain, and the PID (the difference in NRS pain intensity between each time point and Time 0) at each time point was calculated.
| score on a scale | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| PID 15 Minutes Post-dose | 0.4 ± 0.97 | 0.5 ± 1.14 | 0.2 ± 0.99 |
| PID 30 Minutes Post-dose | 1.4 ± 1.79 | 1.5 ± 1.90 | 0.3 ± 1.34 |
| PID 45 Minutes Post-dose | 2.1 ± 2.37 | 2.6 ± 2.25 | 0.3 ± 1.57 |
| PID 1 Hour Post-dose | 2.9 ± 2.59 | 3.5 ± 2.51 | 0.4 ± 2.02 |
| PID 1.5 Hours Post-dose | 3.8 ± 2.76 | 4.4 ± 2.41 | 0.3 ± 2.09 |
| PID 2 Hours Post-dose | 4.3 ± 2.78 | 5.0 ± 2.38 | 0.4 ± 2.39 |
| PID 3 Hours Post-dose | 4.5 ± 2.81 | 5.2 ± 2.27 | 0.3 ± 2.56 |
| PID 4 Hours Post-dose | 4.8 ± 2.92 | 5.2 ± 2.27 | 0.3 ± 2.59 |
| PID 5 Hours Post-dose | 4.6 ± 2.79 | 5.0 ± 2.16 | 0.6 ± 2.84 |
| PID 6 Hours Post-dose | 5.1 ± 2.10 | 4.8 ± 2.19 | 3.2 ± 3.12 |
| PID 7 Hours Post-dose | 5.0 ± 2.25 | 4.3 ± 2.29 | 3.0 ± 2.70 |
| PID 8 Hours Post-dose | 4.6 ± 2.32 | 3.6 ± 2.31 | 3.0 ± 2.73 |
| PID 10 Hours Post-dose | 5.1 ± 2.10 | 5.4 ± 2.03 | 2.0 ± 2.75 |
| PID 12 Hours Post-dose | 4.6 ± 2.21 | 5.6 ± 1.92 | 2.1 ± 3.60 |
| PID 16 Hours Post-dose | 5.2 ± 2.34 | 4.8 ± 2.26 | 3.2 ± 2.99 |
| PID 24 Hours Post-dose | 5.6 ± 2.20 | 5.9 ± 1.68 | 3.9 ± 3.24 |
Pain intensity score at each scheduled time point will be assessed using a numeric rating scale (NRS) for pain. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain.
| score on a scale | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Pain Intensity Score at Baseline | 7.5 ± 1.23 | 7.6 ± 1.17 | 7.8 ± 1.12 |
| Pain Intensity Score 15 Minutes Post-dose | 7.1 ± 1.59 | 7.1 ± 1.61 | 7.6 ± 1.33 |
| Pain Intensity Score 30 Minutes Post-dose | 6.1 ± 2.06 | 6.1 ± 2.24 | 7.5 ± 1.62 |
| Pain Intensity Score 45 Minutes Post-dose | 5.5 ± 2.50 | 5.0 ± 2.57 | 7.6 ± 1.74 |
| Pain Intensity Score 1 Hour Post-dose | 4.7 ± 2.68 | 4.0 ± 2.67 | 7.4 ± 2.06 |
| Pain Intensity Score 1.5 Hours Post-dose | 3.8 ± 2.79 | 3.2 ± 2.48 | 7.5 ± 2.08 |
| Pain Intensity Score 2 Hours Post-dose | 3.2 ± 2.79 | 2.6 ± 2.39 | 7.4 ± 2.37 |
| Pain Intensity Score 3 Hours Post-dose | 2.9 ± 2.84 | 2.4 ± 2.26 | 7.6 ± 2.46 |
| Pain Intensity Score 4 Hours Post-dose | 2.7 ± 2.89 | 2.3 ± 2.30 | 7.6 ± 2.52 |
| Pain Intensity Score 5 Hours Post-dose | 2.9 ± 2.88 | 2.6 ± 2.28 | 7.2 ± 2.71 |
| Pain Intensity Score 6 Hours Post-dose | 2.4 ± 2.05 | 2.8 ± 2.16 | 4.7 ± 2.78 |
| Pain Intensity Score 7 Hours Post-dose | 2.5 ± 2.32 | 3.3 ± 2.34 | 4.8 ± 2.53 |
| Pain Intensity Score 8 Hours Post-dose | 2.9 ± 2.46 | 4.0 ± 2.48 | 4.8 ± 2.54 |
| Pain Intensity Score 10 Hours Post-dose | 2.4 ± 2.34 | 2.2 ± 1.92 | 5.8 ± 2.53 |
| Pain Intensity Score 12 Hours Post-dose | 2.9 ± 2.30 | 2.0 ± 1.80 | 5.7 ± 3.18 |
| Pain Intensity Score 16 Hours Post-dose | 2.3 ± 2.26 | 2.8 ± 2.23 | 4.6 ± 2.74 |
| Pain Intensity Score 24 Hours Post-dose | 1.8 ± 2.09 | 1.7 ± 1.53 | 3.9 ± 3.01 |
Pain relief score at each scheduled time point after Time 0 was measured using the Pain Relief Scale (PRS). The PRS was used to measure pain relief and is a 5-point categorical scale, with response choices of: none = 0; a little = 1; some = 2; a lot = 3; and complete = 4 to be completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome.
| score on a scale | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| 15 Minutes Post-dose | 0.3 ± 0.60 | 0.4 ± 0.67 | 0.3 ± 0.44 |
| 30 Minutes Post-dose | 0.9 ± 0.92 | 1.0 ± 0.93 | 0.4 ± 0.72 |
| 45 Minutes Post-dose | 1.3 ± 1.10 | 1.6 ± 1.15 | 0.5 ± 0.79 |
| 1 Hour Post-dose | 1.7 ± 1.22 | 1.9 ± 1.21 | 0.6 ± 0.88 |
| 1.5 Hours Post-dose | 2.1 ± 1.26 | 2.4 ± 1.13 | 0.5 ± 0.88 |
| 2 Hours Post-dose | 2.3 ± 1.22 | 2.6 ± 1.08 | 0.6 ± 1.00 |
| 3 Hours Post-dose | 2.5 ± 1.31 | 2.7 ± 0.97 | 0.5 ± 1.00 |
| 4 Hours Post-dose | 2.6 ± 1.39 | 2.7 ± 1.00 | 0.5 ± 0.97 |
| 5 Hours Post-dose | 2.5 ± 1.34 | 2.6 ± 1.01 | 0.7 ± 1.10 |
| 6 Hours Post-dose | 2.7 ± 0.96 | 2.5 ± 0.99 | 1.8 ± 1.29 |
| 7 Hours Post-dose | 2.7 ± 1.06 | 2.3 ± 1.12 | 1.7 ± 1.21 |
| 8 Hours Post-dose | 2.5 ± 1.11 | 2.1 ± 1.15 | 1.7 ± 1.23 |
| 10 Hours Post-dose | 2.7 ± 1.06 | 2.9 ± 0.94 | 1.3 ± 1.16 |
| 12 Hours Post-dose | 2.5 ± 1.04 | 2.9 ± 0.88 | 1.2 ± 1.27 |
| 16 Hours Post-dose | 2.8 ± 1.06 | 2.6 ± 1.03 | 1.8 ± 1.34 |
| 24 Hours Post-dose | 3.0 ± 0.96 | 3.1 ± 0.74 | 2.1 ± 1.43 |
Peak pain relief at each time point was measured using the Pain Relief Scale (PRS). The PRS was used to measure pain relief and is a 5-point categorical scale, response choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4 to be completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome. For each subject, peak pain relief was calculated as the maximum pain relief over all PRS assessments, and summarised by counts (and percentages) for each PRS score. Peak pain relief was calculated from PRS scores that were adjusted for rescue medication usage using windowed worst observation carried forward (WOCF).
| Participants | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| None | 2 | 1 | 0 |
| A little relief | 2 | 1 | 2 |
| Some relief | 8 | 3 | 8 |
| A lot of relief | 49 | 62 | 23 |
| Complete relief | 59 | 53 | 6 |
Two stopwatches were started immediately after the subject swallowed the study drug. Subjects were instructed to, "Stop the first stopwatch when you first feel any pain relief whatsoever. This does not mean you feel completely better, although you might, but when you first feel any relief in the pain you have now" (perceptible pain relief), and then, "Stop the second stopwatch when you feel the pain relief is meaningful to you" (meaningful pain relief). If the stopwatches were not stopped within 8 hours after Time 0 use of the stopwatches was discontinued. If the subject had meaningful pain relief (i.e., pressed both stopwatches) then time to onset of analgesia was date/time of perceptible pain relief - date/time of the first dose of study drug. Values presented are from Kaplan-Meier estimates.
| Hours | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Time to Onset of Analgesia (Measured as Time to Perceptible Pain Relief Confirmed by Time to Meaningful Pain Relief) Using Double Stopwatch | 0.48 (0.42 to 0.53) | 0.47 (0.37 to 0.51) | NA (NA to NA) |
Two stopwatches were started immediately after the subject swallowed the study drug. Subjects were instructed to, "Stop the first stopwatch when you first feel any pain relief whatsoever. This does not mean you feel completely better, although you might, but when you first feel any relief in the pain you have now" (perceptible pain relief). Time to first perceptible pain relief was date/time of the first reported pain relief (any) as assessed by the subject (i.e., when the subject stopped the first stopwatch, irrespective of the second) - date/time of the first dose of study drug. If the stopwatch were not stopped within 8 hours after Time 0, use of the stopwatches was discontinued. Values presented are from Kaplan-Meier estimates.
| Hours | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Time to First Perceptible Pain Relief | 0.47 (0.09 to 5.11) | 0.46 (0.04 to 3.96) | 1.01 (0.08 to 3.28) |
Two stopwatches were started immediately after the subject swallowed the study drug. Each subject was instructed, "Stop the second stopwatch when you feel the pain relief is meaningful to you" (meaningful pain relief). Time to meaningful pain relief was the date/time of the first reported meaningful (subjective) pain relief as assessed by the subject (i.e., when the subject stopped the second stopwatch) - date/time of the first dose of study drug. If the stopwatches were not stopped within 8 hours after Time 0 use of the stopwatches was discontinued. Values presented are from Kaplan-Meier estimates.
| Hours | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Time to Meaningful Pain Relief | 1.25 (0.21 to 8.00) | 0.99 (0.29 to 8.00) | 2.88 (0.32 to 7.95) |
The PRS was used to measure pain relief and is a 5-point categorical scale, with response choices of: none = 0; a little = 1; some = 2; a lot = 3; and complete = 4 to be completed in response to the question "How much relief have you had since your starting pain?". A higher score indicates greater pain. Time to peak pain relief was the time when peak pain relief (PPR) first occurred. Values presented are from Kaplan-Meier estimates.
| Hours | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Time to Peak Pain Relief | 3.00 (2.03 to 3.97) | 2.02 (1.98 to 3.00) | 5.02 (3.02 to 11.97) |
After randomisation and administration of study drug, paracetamol/acetaminophen (1000 mg) was permitted as the initial rescue medication. Subjects were encouraged to wait at least 60 minutes after receiving study drug before taking rescue medication. If acetaminophen rescue medication was not effective in relieving the subject's pain, 5 mg oxycodone rescue medication was administered at the discretion of the investigator. At the investigator's discretion, repeat doses of rescue medication were also administered as required.
| Participants | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Number of Subjects Using Rescue Medication | 30 | 19 | 32 |
Time to first use of rescue medication, in hours.
| hours | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Time to First Use of Rescue Medication (Median and 95% Confidence Interval) | NA (NA to NA) | NA (NA to NA) | 1.37 (1.20 to 2.38) |
Time to first use of rescue medication, in hours. Values presented are the hazard ratios, calculated from Cox proportional hazards model with treatment group as a categorical factor and baseline pain as a continuous covariate. A hazard ratio of \<1 means that when subjects did take rescue medication, subjects in the ibuprofen groups refrained from taking rescue medication for longer than subjects in the placebo group. A hazard ratio of \>1 means that when subjects did take rescue medication, subjects in the placebo group refrained from taking rescue medication for longer than subjects in the ibuprofen groups.
| Hazard ratio versus placebo | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| Time to First Use of Rescue Medication (Hazard Ratios Versus Placebo) | 0.17 (0.10 to 0.29) | 0.10 (0.06 to 0.18) | NA (NA to NA) |
Incidence of treatment emergent adverse events (TEAEs). Data listings will be provided for protocol specified safety data.
Results for this outcome have not been posted.
Incidence of changes in vital sign measurements. Descriptive statistics will be provided at each scheduled time point for each treatment group. Changes from Baseline for vital signs will be calculated for each subject.
Results for this outcome have not been posted.
Incidence of changes in vital sign measurements. Descriptive statistics will be provided at each scheduled time point for each treatment group. Changes from Baseline for vital signs will be calculated for each subject.
Results for this outcome have not been posted.
Incidence of changes in vital sign measurements. Descriptive statistics will be provided at each scheduled time point for each treatment group. Changes from Baseline for vital signs will be calculated for each subject.
Results for this outcome have not been posted.
Incidence of changes in vital sign measurements. Descriptive statistics will be provided at each scheduled time point for each treatment group. Changes from Baseline for vital signs will be calculated for each subject.
Results for this outcome have not been posted.
Patient's global evaluation of study drug using 5 point categorical scale, response choices of 0 = poor, 1 = fair, 2 = good, 3 = very good, or 4 = excellent to be completed by the patient in response to the question "How effective do you think the study drug is as a treatment for pain?". Subjects will complete the global evaluation of study drug 24 hours after Time 0 or immediately before the first dose of rescue medication (whichever occurs first).
Results for this outcome have not been posted.
Collected over Adverse events were monitored and recorded from the time of signing of the informed consent form until the Follow-up Visit (or Early Termination Visit); a period of up to 30 days. Only treatment-emergent adverse events (those that started or worsened in intensity or relationship to treatment on or after the first dose of study drug) are reported here.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prolonged Release Group | 0/120 (0%) | 0/120 (0%) | 11/120 (9.2%) |
| Immediate Release Group | 0/120 (0%) | 0/120 (0%) | 15/120 (12.5%) |
| Placebo Group | 0/39 (0%) | 0/39 (0%) | 12/39 (30.8%) |
| Event | Prolonged Release Group | Immediate Release Group | Placebo Group |
|---|---|---|---|
| NauseaGastrointestinal disorders | 1/120 | 2/120 | 6/39 |
| VomitingGastrointestinal disorders | 0/120 | 2/120 | 3/39 |
| RashSkin and subcutaneous tissue disorders | 0/120 | 0/120 | 2/39 |
| ChillsGeneral disorders | 0/120 | 0/120 | 1/39 |
| Swelling faceGeneral disorders | 0/120 | 1/120 | 1/39 |
| Alveolar osteitisInfections and infestations | 1/120 | 1/120 | 1/39 |
| Tooth infectionInfections and infestations | 0/120 | 0/120 | 1/39 |
| Product administration errorInjury, poisoning and procedural complications | 0/120 | 0/120 | 1/39 |
| DizzinessNervous system disorders | 0/120 | 0/120 | 1/39 |
| HeadacheNervous system disorders | 0/120 | 2/120 | 1/39 |
One subject in the placebo group withdrew from the study before receiving the allocation intervention.
| Age, Continuous(years) | Prolonged Release Group | Immediate Release Group | Placebo Group | Total |
|---|---|---|---|---|
| Mean | 19.6 ± 2.02 | 19.8 ± 2.47 | 20.7 ± 3.13 | 19.8 ± 2.42 |
| Sex: Female, Male(Participants) | Prolonged Release Group | Immediate Release Group | Placebo Group | Total |
|---|---|---|---|---|
| Female | 72 | 53 | 24 | 149 |
| Male | 48 | 67 | 15 | 130 |
| Ethnicity (NIH/OMB)(Participants) | Prolonged Release Group | Immediate Release Group | Placebo Group | Total |
|---|---|---|---|---|
| Hispanic or Latino | 17 | 12 | 8 | 37 |
| Not Hispanic or Latino | 101 | 105 | 30 | 236 |
| Unknown or Not Reported | 2 | 3 | 1 | 6 |
| Race (NIH/OMB)(Participants) | Prolonged Release Group | Immediate Release Group | Placebo Group | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 0 | 2 |
| Asian | 3 | 2 | 1 | 6 |
| Native Hawaiian or Other Pacific Islander | 5 | 2 | 2 | 9 |
| Black or African American | 2 | 1 | 0 | 3 |
| White | 107 | 108 | 36 | 251 |
| More than one race | 1 | 2 | 0 | 3 |
| Unknown or Not Reported | 1 | 4 | 0 | 5 |
| Baseline Pain(units on a scale) | Prolonged Release Group | Immediate Release Group | Placebo Group | Total |
|---|---|---|---|---|
| Mean | 7.5 ± 1.23 | 7.6 ± 1.17 | 7.8 ± 1.12 | 7.6 ± 1.19 |
| Baseline Pain Category(Participants) | Prolonged Release Group | Immediate Release Group | Placebo Group | Total |
|---|---|---|---|---|
| Moderate | 63 | 57 | 15 | 135 |
| Severe | 57 | 63 | 24 | 144 |
| Height(cm) | Prolonged Release Group | Immediate Release Group | Placebo Group | Total |
|---|---|---|---|---|
| Mean | 168.72 ± 9.753 | 171.61 ± 8.517 | 167.85 ± 6.223 | 169.84 ± 8.917 |
| Weight(kg) | Prolonged Release Group | Immediate Release Group | Placebo Group | Total |
|---|---|---|---|---|
| Mean | 67.99 ± 13.931 | 73.17 ± 13.921 | 69.69 ± 12.041 | 70.46 ± 13.847 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2019 to primary completion in Feb 2020, 9 months.
Results were first posted in Jun 2024, 4 years 3 months after primary completion.
Of 105 industry-sponsored phase 3 interventional studies under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's 9 months is below that.
Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibuprofen
Reckitt Benckiser Healthcare (UK) Limited →